# Pizarra — PT-pseudo_1dc32184cab6 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_1dc32184cab6
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 0.76 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.02 ng/mL²
  - PSA velocity: 0.17 ng/mL/yr
  - Prior PSA: 0.6 ng/mL
  - Prostate volume: 36.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.39141726 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 0.76 ng/mL. PI-RADS 4. PSAD 0.02. Prostate volume 36 mL. csPCa 0.39.

Vitals: weight 84 kg, height 169 cm, BMI 29.4, BP 115/77 mmHg, HR 64 bpm. Smoking: Ex-smoker (21 pack-yr, quit 2010).

Chief complaint: Clinical reassessment follows a documented history of benign prior biopsies alongside a progressively ascending prostate-specific antigen trajectory.

History: At sixty years of age, the patient works as a primary school teacher and occupies an independent unit within a retirement community. Never married, he relies on his partner for primary communication. A gradual increase in prostate-specific antigen prompted initial investigation three years ago. Lower urinary tract symptoms generate an IPSS score of 20, though he firmly denies haematuria or acute retention episodes. Physical mobility restricts him to chair-based exercises, and he completely abstains from alcohol. A routine chest radiograph conducted last month showed no abnormalities, and his surgical history is limited to a minor knee arthroscopy performed during his forties. No comorbidities or active medications exist. Mild anxiety accompanies the biopsy results, yet he remains otherwise well. He previously smoked twenty-one pack-years before ceasing in 2010.

Physical examination: Per rectum: the gland measures symmetrically enlarged, presenting a smooth and firm consistency without palpable nodules or asymmetry. General assessment proves unremarkable, characterized by clear lung fields and a regular cardiovascular rhythm. The abdomen remains soft and non-tender, with no detectable masses or organomegaly.

Patient info: primary school teacher; Never married; Lives in retirement community (independent unit).
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Limited mobility — chair-based exercises only; IPSS score: 20/35 (severe LUTS).

Recent other appointments: Radiology — chest X-ray (routine).
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.74 +/- 0.21   (95% CI 0.33-1.00)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.21  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.83 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'supports': p +/- dp does not cross 0.5 but p +/- 1.96*dp does. A direction, not a conclusion; a weighted vote. Measured accuracy in this tier on the labelled cohort: 0.8 over 20 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
  - psa_trend (get_psa_trend) -> Does the PSA trend suggest a change in trajectory that alters the decision?
  - previous_notes (get_previous_notes) -> What was the prior management context, including prior grade and surveillance pathway?

This case hinges on the mpMRI findings and the history of prior negative biopsy, as the statistical prior and protocol criterion are inconclusive without the detailed reports.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed structured panel data (PSA 0.76, PI-RADS 4, prior negative biopsy, etc.). It could not weigh the specific context of the mpMRI prose, the PSA velocity (0.17 ng/mL/yr), or the specific findings from the previous notes or lab panel. It also did not account for the clinical context of the LUTS (IPSS 20) or the patient's functional status (limited mobility).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy (p=0.74) despite the guideline criterion being "BIOPSY" based on PI-RADS 4, which might be overly aggressive given the prior negative biopsy. The high aleatoric uncertainty (H=0.83) suggests the model struggles with this specific scenario, possibly because the prior negative biopsy should heavily influence the decision, which the model may have undervalued.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
psa_trend - Does the PSA trend suggest a change in trajectory that alters the decision?
previous_notes - What was the prior management context, including prior grade and surveillance pathway?
laboratory panel - What are the specific lab values that might influence the risk stratification (e.g., PSA density)?
GUIDELINE ANCHOR
The guideline criterion states: "Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed."

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Radiology Division | Catharina Ziekenhuis, Eindhoven | 20 Feb 2025 | Exam: Multiparametric MRI Prostate
FINDINGS: The gland measures 36.0 mL in volume, exhibiting asymmetric enlargement. A focal hypointense focus occupies the right peripheral zone at the mid-gland posterior aspect, spanning roughly 12 x 8 x 10 mm. Diffusion-weighted sequences reveal pronounced restricted diffusion alongside correspondingly low ADC values. Dynamic contrast-enhanced sequences demonstrate early focal enhancement compared to adjacent parenchyma. Extracapsular extension and seminal vesicle invasion are absent. Pelvic lymph nodes appear normal.
IMPRESSION: PI-RADS 4 lesion in the right mid-peripheral zone. PSAD: 0.02 ng/mL/mL. csPCa predicted probability 0.39141726

get_psa_trend
{"date": "Oct 2022", "val": 0.5}, {"date": "Jul 2023", "val": 0.6}, {"date": "May 2024", "val": 0.7}, {"date": "Feb 2025", "val": 0.76}

get_previous_notes
{"date": "29 Oct 2024", "author": "Dr. P. van Dijk (GP)", "text": "Clinical review focused on tracking a previously elevated prostate-specific antigen. A prior systematic biopsy returned negative results. The measured value climbed to 0.6 ng/mL, prompting a urology referral for deeper assessment. The individual notes ongoing lower urinary tract symptoms, explicitly ruling out haematuria or bone pain."}, {"date": "03 Mar 2024", "author": "Dr. P. van Dijk (GP)", "text": "Scheduled monitoring tracked the prostate-specific antigen trend. The preceding measurement held steady at 0.4 ng/mL. No symptoms of acute urinary retention were reported. Lower urinary tract symptoms required only conservative management through lifestyle adjustments."}

NOT RETRIEVED
laboratory panel
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no specific question arose from the retrieved documents that necessitated its opening.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 4 lesion in the right mid-peripheral zone.
- PSA trend: PSA velocity of 0.17 ng/mL/yr, showing a clear ascending trajectory from 0.5 ng/mL in Oct 2022 to 0.76 ng/mL in Feb 2025.
- Previous notes: Prior biopsy was negative, and the patient is being re-evaluated due to a progressively ascending PSA trajectory.

AGAINST sampling this patient now:
- Previous notes: Prior biopsy was negative.

WHERE THIS LEANS
The evidence strongly supports re-biopsy due to the presence of a PI-RADS 4 lesion and a clear upward trend in PSA, aligning with the expert protocol criterion.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (mpMRI showing PI-RADS 4 and an ascending PSA trend combined with a prior negative biopsy) strongly supports the guideline criterion for biopsy. The record is sufficient to proceed to the final decision.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to recommend biopsy is supported by convergence across all inputs. The guideline criterion mandates re-biopsy for a PI-RADS 4-5 lesion, which was confirmed by the retrieved mpMRI report showing a PI-RADS 4 lesion. This finding, combined with the prior negative biopsy status, is decisive. Furthermore, the ascending PSA trend, moving from 0.5 ng/mL in Oct 2022 to 0.76 ng/mL in Feb 2025, reinforces the need for further investigation. The statistical prior also supported this recommendation, leading to a clear consensus.

Variables that carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
